CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 ex...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Pollard, Jessica A., Loken, Michael, Gerbing, Robert B., Raimondi, Susana C., Hirsch, Betsy A., Aplenc, Richard, Bernstein, Irwin D., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2016
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872025/
https://ncbi.nlm.nih.gov/pubmed/26786921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.6846
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items